| Delaware (State or other jurisdiction of incorporation or organization | | | 75-3175693 (I. R. S. Employer Identification No.) | |
| 4 Stamford Plaza 107 Elm Street, 9th Floor Stamford, Connecticut 06902 (203) 406-3700 | |
| Christopher Posner Chief Executive Officer Cara Therapeutics, Inc. 4 Stamford Plaza 107 Elm Street, Ninth Floor Stamford, Connecticut 06902 (203) 406-3700 | |
| Copies to: Darren DeStefano Nicolas H.R. Dumont Cooley LLP 11951 Freedom Drive, 14th Floor Reston, VA 20190-5640 (703) 456-8000 | |
| From time to time after the effective date of this Registration Statement (Approximate date of commencement of proposed sale to the public) | |
| Large accelerated filer ☒ | | | Accelerated filer ☐ | |
| Non-accelerated filer ☐ | | | Smaller reporting company ☐ | |
| | | | Emerging Growth Company ☐ | |
| Assumed public offering price per share | | | | | | | | | | $ | 10.46 | | |
| Net tangible book value per share as of December 31, 2021 | | | | $ | 4.25 | | | | | | | | |
| Increase in net tangible book value per share attributable to this offering | | | | $ | 0.74 | | | | | | | | |
| As adjusted net tangible book value per share as of December 31, 2021, after giving effect to this offering | | | | | | | | | | $ | 4.99 | | |
| Dilution per share to investors purchasing our common stock in this offering | | | | | | | | | | $ | 5.47 | | |
| SEC registration fee | | | | $ | 27,810 | | |
| Accounting fees and expenses | | | | | * | | |
| Legal fees and expenses | | | | | * | | |
| Transfer agent fees and expenses | | | | | * | | |
| Trustee fees and expenses | | | | | * | | |
| Printing and miscellaneous expenses | | | | | * | | |
| Total | | | | $ | * | | |
Exhibit Number | | | Description of Document | | ||||
| | 1.1(1) | | | | Form of Underwriting Agreement | | |
| | 1.2(6) | | | | | ||
| | 3.1(2) | | | | | ||
| | 3.2(3) | | | | | ||
| | 4.1(4) | | | | | ||
| | 4.2(6) | | | | | ||
| | 4.3(1) | | | | Form of Note | | |
| | 4.4(6) | | | | | ||
| | 4.5(6) | | | | | ||
| | 4.6(6) | | | | | ||
| | 4.7(1) | | | | Form of Specimen Preferred Stock Certificate and Certificate of Designations of Preferred Stock | | |
| | 4.8(5) | | | | | ||
| | 5.1(6) | | | | | ||
| | 23.1 | | | | | ||
| | 23.2(6) | | | | | ||
| | 24.1(6) | | | | | ||
| | 25.1(1) | | | | Statement of Eligibility of Trustee under the Debt Indenture | | |
| | 107(6) | | | | |
| | | | CARA THERAPEUTICS, INC. | | |||
| | | | By: | | | /s/ CHRISTOPHER POSNER Christopher Posner Chief Executive Officer | |
| Signature | | | Title | | | Date | |
| Christopher Posner | | | President, Chief Executive Officer and Director(Principal Executive Officer) | | | | |
| Thomas Reilly | | | Chief Financial Officer(Principal Financial and Accounting Officer) | | | | |
| Martin Vogelbaum | | | Director | | | | |
| Harrison M. Bains, Jr. | | | Director | | | | |
| Jeffrey Ives, Ph.D. | | | Director | | | | |
| Susan Shiff | | | Director | | | |
| * By: /s/ Thomas Reilly Thomas Reilly, Attorney-in-Fact | | | | | | | |